User Guide
Why can I only view 3 results?
You can also view all results when you are connected from the network of member institutions only. For non-member institutions, we are opening a 1-month free trial version if institution officials apply.
So many results that aren't mine?
References in many bibliographies are sometimes referred to as "Surname, I", so the citations of academics whose Surname and initials are the same may occasionally interfere. This problem is often the case with citation indexes all over the world.
How can I see only citations to my article?
After searching the name of your article, you can see the references to the article you selected as soon as you click on the details section.
 Views 9
 Downloands 2
Yüzeyel mesane tümörlerinde TUR sonrası intravezikal BCG tedavisinin etkinliği
2012
Journal:  
The New Journal of Urology
Author:  
Abstract:

Objective: The aim of this study is to determine whether BCG vaccine has the same effectivenes in the prevention of recurrences after TUR in patients with primary or recurrent group. In addition, to determine the predictive value of ppd test positivity for tumor recurency.Materials and Methods: 94 patients 43 primary tumor and 51 recurrent tumor enrolled to this study. All patients underwent TUR. By starting 15 days after surgery, 81 mg of intravesical BCG was administered for a 6 weeks duration. The treatment postponed or canceled for the patients who have severe hematuria or can not tolerate the treatment as well. Patients were checked by cystoscopy and urine cytology in the first year quarterly, in the second and third year by 6 monthly. PPD tests were performed before and after BCG treatment and recorded in both primary and recurrent groups. In both group, the number of tumor recurrence every months, monthly recurrence indexes and recurrence rates of 100 monthly were analyzed. The Chi-square test was used to compare results.Results: Eighty-two male and 12 female patients included to this study The average age is 57.6 . Fourty three of 94 patients with primary superficial bladder cancer and 51 patients were recurrent group because of they received at least one prior therapy only TUR, TUR + epirubicin or TUR+interferon .The ppd test was negative in 33 of 43 patients in primary group TUR plus intravesical hastanın sadece 8’inde ppd testi, tedavi sonrasında da negatif olarak kaldı. Bu 8 hastanın 6’sında %75 ileri dönemlerde rekürens görüldü.Rekürens grubunda ise tedavi öncesinde 51 hastanın 29’unda ppd testi negatifti. Bu sayı tedavi sonrasında 15’e düştü ve bu 15 hastanın 12’ sinde %80 rekürens saptandı. Ayrıca rekürrens grubunda tedavi öncesi ve tedavi sonrası ppd testleri pozitif olan 12 hastanın 2’sinde %16,6 tedavi öncesi negatif olup tedavi sonrası pozitif olan 14 hastanın 1’inde %7,1 rekürens saptandı. BCG tedavisine bağlıönemli yan etkiler dizüri ve mikroskopik hematüriydi ve bu yan etkiler tedavinin kesilmesini gerektirmedi.Primer grupta 0.010 olan rekürens indeksi, reküren grupta tedavi öncesi 0.183 iken tedavi sonrası 0.208 olarak saptandı. Test sonuçlarına göre rekürren grupta tedavi öncesi ve sonrası değerler arasındaki fark istatistiksel olarak anlamlı değildi P: 0,53 . Primer grup ile rekürren grup arasında ise rekürens açısından anlamlı derecede fark olduğunu saptadı p

Keywords:

Citation Owners
Information: There is no ciation to this publication.
Similar Articles








The New Journal of Urology

Journal Type :   Uluslararası

Metrics
Article : 518
Cite : 74
The New Journal of Urology